Blacks and Whites Have Similar Outcomes After PCI Blacks and Whites Have Similar Outcomes After PCI
A study designed to look for differing outcomes when black and white U.S. veterans undergo percutaneous coronary intervention (PCI) instead found no differences once confounding factors were taken into account.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 25, 2017 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news
Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
REDWOOD CITY, Calif., July 25, 2017 -- (Healthcare Sales & Marketing Network) -- Roxwood Medical Inc., a leading provider of advanced cardiovascular specialty catheters, today announced it has entered into an exclusive agreement with Abbott for distributi... Devices, Interventional, Cardiology, Distribution Roxwood Medical, Abbott, CenterCross, Percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news
Firefighter ™ PTCA Balloon Catheter Gains CFDA Approval
(Source: Microport News Release)
Source: Microport News Release - July 24, 2017 Category: Medical Devices Source Type: news
Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)
Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year (...
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news
21.07.17: Not intended for U.S. and UK Media
Bayer's Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent PlacementPositive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent...
Source: Bayer IR Newsfeed: Events - July 20, 2017 Category: Pharmaceuticals Source Type: news
Heart vessel-clearing procedure can benefit some at age 90 and older
People in their nineties and older represent a tiny but growing fraction of patients who undergo a procedure called percutaneous coronary intervention (PCI) to clear blocked blood vessels in the heart, new research shows. (Source: Reuters: Health)
Source: Reuters: Health - July 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Firefighter ™ PTCA Balloon Dilatation Catheter Gains Regulatory Approval in Brazil
(Source: Microport News Release)
Source: Microport News Release - July 7, 2017 Category: Medical Devices Source Type: news
Prolonged DAPT After PCI: Risk Score Helps Identify Those Most Likely to Be Harmed (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
The DAPT (dual antiplatelet therapy) score helps identify patients for whom prolonged treatment after percutaneous coronary intervention would be harmful, suggests an analysis in the Annals of Internal Medicine. Researchers retrospectively applied … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 13, 2017 Category: Primary Care Source Type: news
No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news
MassDevice.com +5 | The top 5 medtech stories for May 16, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Corindus touts high success rate in CorPath 200 PCI registry study
Corindus Vascular Robotics today released post-market findings from the Precision registry study of its CorPath 200 system used during percutaneous coronary int...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Abbott recalls heart catheters on balloon sheath issue
Abbott (NYSE:ABT) is recalling some 450,000 coronary catheters on the risk that removing a protective balloon sheath can damage the ballon during angioplasty procedures.
In a March 22 letter to customers, Abbot said the recall affects its NC Trek RX and NC Traveler RX coronary dilatation catheters and the NC Tenku RX PTCA balloon catheter.
“Product from the identified lots may exhibit difficulty in removing the protective balloon sheath which can result in issues with inflating or deflating the balloon,” Abbott said. “If excessive force is required to remove the balloon sheath, the sheath may damage th...
Source: Mass Device - May 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Food & Drug Administration (FDA) Recalls Regulatory/Compliance Abbott Source Type: news
Abbott Initiates Voluntarily Recall of Specific Lots of Three Coronary Catheters
Abbott has initiated a voluntary recall of specific lots of three catheters: NC Trek RX Coronary Dilatation Catheter, NC Traveler Coronary Dilatation Catheter, and NC Tenku RX PTCA Balloon Catheter. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 15, 2017 Category: Food Science Source Type: news
Large multicenter study shows high success rate for robotic PCI procedures
Results from the PRECISION trial (Efficacy and Safety Outcomes of Radial- vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry) were presented today as a late-breaking clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2017 Category: Science Source Type: news
Blood Vessel-Clearing Procedure Riskier on Weekends: Study
THURSDAY, May 11, 2017 -- Although you often don ' t have a choice of when you get the heart procedure called percutaneous coronary intervention (PCI), new research suggests that having it done over the weekend may be more risky.
The study reported... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 11, 2017 Category: General Medicine Source Type: news
Abiomed dips on missed Q4 earnings, despite sales beat
Share prices for Abiomed (NSDQ:ABMD) dipped today after the company reported fiscal 4th-quarter earnings that missed expectations, despite a top-line gain of nearly 33%.
The Danvers, Mass.-based heart pump maker posted profits of $14.9 million, or 33¢ per share, on sales of $124.7 million for the 3 months ended March 31, for a bottom-line increase of 35.5% on sales growth of 32.7% compared with Q4 2016.
But analysts on Wall Street were looking for earnings per share of 35¢; Abiomed topped the consensus Street estimate for sales by more than $2 million.
Full-year profits were $52.1 million, or $1.17 per share, on sales o...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news
